EXACT Therapeutics AS (OSL:EXTX)
Norway
· Delayed Price · Currency is NOK 1.480
+0.050 (3.50%)
At close: Apr 28, 2026
EXACT Therapeutics AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Other Revenue | 0.06 | - | 0 | 0.45 | 0.05 | Upgrade
|
| Revenue | 0.06 | - | 0 | 0.45 | 0.05 | Upgrade
|
| Revenue Growth (YoY) | - | - | -99.02% | 774.07% | - | Upgrade
|
| Gross Profit | 0.06 | - | 0 | 0.45 | 0.05 | Upgrade
|
| Selling, General & Admin | 28.98 | 23.36 | 22.55 | 14.58 | 18.52 | Upgrade
|
| Research & Development | 40.54 | 18.52 | - | - | - | Upgrade
|
| Other Operating Expenses | 11.73 | 8.54 | 23.74 | 24.64 | 38.83 | Upgrade
|
| Operating Expenses | 84.94 | 52.85 | 48.38 | 41.23 | 59.16 | Upgrade
|
| Operating Income | -84.88 | -52.85 | -48.38 | -40.77 | -59.11 | Upgrade
|
| Interest Expense | -0.03 | -0.05 | -0.09 | -0.1 | -0.1 | Upgrade
|
| Interest & Investment Income | 2.62 | 0.92 | 0.95 | 0.48 | 0.34 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.68 | -0.35 | -1.12 | 0.22 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | 0 | 0.25 | -0.4 | 0.27 | Upgrade
|
| EBT Excluding Unusual Items | -86.97 | -52.33 | -48.38 | -40.57 | -58.59 | Upgrade
|
| Pretax Income | -86.97 | -52.33 | -48.38 | -40.57 | -58.59 | Upgrade
|
| Income Tax Expense | - | - | -0.05 | -0.46 | - | Upgrade
|
| Net Income | -86.97 | -52.33 | -48.33 | -40.1 | -58.59 | Upgrade
|
| Net Income to Common | -86.97 | -52.33 | -48.33 | -40.1 | -58.59 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 35 | 32 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 35 | 32 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | 82.42% | 8.10% | 6.94% | 0.06% | 0.04% | Upgrade
|
| EPS (Basic) | -1.37 | -1.51 | -1.51 | -1.34 | -1.95 | Upgrade
|
| EPS (Diluted) | -1.37 | -1.51 | -1.51 | -1.34 | -1.95 | Upgrade
|
| Free Cash Flow | -72.31 | -82.05 | -47.39 | -34.1 | -56.74 | Upgrade
|
| Free Cash Flow Per Share | -1.14 | -2.37 | -1.48 | -1.14 | -1.89 | Upgrade
|
| Gross Margin | 100.00% | - | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -143859.87% | - | -1085224.09% | -8971.05% | -113674.66% | Upgrade
|
| Profit Margin | -147402.80% | - | -1084201.23% | -8823.56% | -112673.43% | Upgrade
|
| Free Cash Flow Margin | -122558.79% | - | -1062987.39% | -7503.15% | -109106.39% | Upgrade
|
| EBITDA | -81.81 | -51.08 | -46.75 | -39.3 | -57.66 | Upgrade
|
| D&A For EBITDA | 3.07 | 1.77 | 1.63 | 1.48 | 1.45 | Upgrade
|
| EBIT | -84.88 | -52.85 | -48.38 | -40.77 | -59.11 | Upgrade
|
| Revenue as Reported | 0.06 | - | 0 | 0.45 | 0.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.